Effect of omega-3 polyunsaturated fatty acids supplementation for patients with osteoarthritis: a meta-analysis

Table 1 Characteristics of the included studies

Study	Country	Study design	OA site	Sample size	Mean age	Men	n-3 PUFA dose	EPA dose	DHA dose	Control	Follow-up duration	Outcomes reported
Study	Country	Study design	OA site	Sample size	years	%	mg/d	mg/d	mg/d	Control	months	Outcomes reported
Stammers 1992	UK	R, DB, PC	Not specified	86	68	27.9	786	786	0	Olive oil	6	VAS for pain and VAS for function
Lau 2004	China	R, DB, PC	Hip or knee	80	62.5	13.8	1360	520	840	Olive oil	6	VAS for pain and PGA for function
Jacquet 2009	France	R, DB, PC	Hip or knee	81	57.1	32.1	1360	520	840	Placebo	3	WOMAC for pain and function
Gruenwald 2009	Germany	R, DB	Hip or knee	177	62.3	36.5	1332	800	532	Palm and sunflower oil	6	WOMAC for pain and function
Suzuki 2016	Japan	R, DB, PC	Knee	47	64.7	12.8	350	240	110	Safflower oil	1	VAS for pain and JOA for function
Stebbings 2017	New Zealand	R, DB, PC	Hip or knee	80	66.4	45	460	280	180	Corn oil	4	WOMAC for pain and function
MacFarlane 2020	USA	R, DB, PC	Knee	1221	67.7	34	840	490	350	Placebo	63	WOMAC for pain and function
Kuszewski 2020	Australia	R, DB, PC	Not specified	63	65.4	NR	2400	400	2000	Corn oil	4	VAS for pain
Stonehouse 2022	Australia	R, DB, PC	Knee	235	55.9	45.1	880	600	280	Vegetable oil	6	WOMAC for pain and function

n-3 PUFA omega-3 polyunsaturated fatty acids; OA osteoarthritis; EPA eicosapentaenoic acid; DHA docosahexanoic acid; R randomized; DB double-blind; PC placebo-controlled; VAS visual analogue scale; PGA Patients’ Global Assessment; WOMAC Western Ontario-McMaster University Osteoarthritis Index; JOA Japanese Orthopaedic Association score

ISSN: 1749-799X